Bellin Behavior Health Bellevue Inc Psychiatry & Neurology - Psychiatry Medicare: Medicare Enrolled Practice Location: 3263 Eaton Road, Green Bay, WI 54311 Phone: 920-445-7222 |
Professional Family Resources & Associates Llc Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2300 Lineville Rd Ste 200, Green Bay, WI 54313 Phone: 920-434-7457 Fax: 920-434-7460 |
Wings Of Eagles Counseling Clinic Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 217 N Madison St, Suite 4, Green Bay, WI 54301 Phone: 920-227-7078 Fax: 920-273-8847 |
Johnson Counseling Llc Clinic - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 3340 Lineville Rd, Green Bay, WI 54313 Phone: 920-486-0376 |
Psychological Consulatnts S.c. Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 130 E. Walunt Street, 604, Green Bay, WI 54301 Phone: 920-437-3854 Fax: 920-437-7488 |
News Archive
How do you tell a little girl that her grandfather, her mother, her friend- has died, and that he or she has gone for ever? Txabi Arnal, a lecturer at the University of the Basque Country (UPV/EHU), has analysed literary picture books that deal with death to see how they address this question.
Type 2 diabetes (T2D) and osteoporosis often coexist in patients, but managing both conditions can be a challenge.
The first disease-modifying drugs are expected to launch from 2013, radically changing the way Alzheimer's disease is treated. With the potential to successfully slow or halt the progression of Alzheimer's, blockbuster revenues are beckoning for such pipeline drugs, claims independent market analyst, Datamonitor.
Devex's "The Development Newswire" quotes a number of leaders in the international community about International Women's Day, observed annually on March 8.
Merck today announced it has entered into a non-exclusive agreement with Bristol-Myers Squibb to conduct a Phase II clinical trial to evaluate the safety and efficacy of a once-daily oral combination regimen consisting of Bristol-Myers Squibb's investigational NS5A replication complex inhibitor daclatasvir and Merck's investigational NS3/4A protease inhibitor MK-5172 for the treatment of chronic hepatitis C virus infection, genotype 1.
› Verified 6 days ago